article thumbnail

Revenue for Fluarix by GSK is expected to have a CAGR of 2.12% through 2038. How does that impact the rNPV of the drug?

Pharmaceutical Technology

Influenza vaccine stimulate the body's immune system to recognize the agent as foreign and destroy it. It also helps the body's immune system to 'remember' the agent, so that the immune system can easily recognize and destroy any of the microbes that it encounters again in the future. Fluarix is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.

article thumbnail

Revenue for Fluarix by GSK is expected to have a CAGR of 2.12% through 2038. How does that impact the rNPV of the drug?

Pharmaceutical Technology

Influenza vaccine stimulate the body's immune system to recognize the agent as foreign and destroy it. It also helps the body's immune system to 'remember' the agent, so that the immune system can easily recognize and destroy any of the microbes that it encounters again in the future. Fluarix is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ivermectin: A therapeutic approach to reduce high-risk cases of COVID

Druggist

Additionally, this drug is also known as anti-parasite successful against all viruses like HIV, Dengue, Influenza , and Zika virus. And stated its judicial use in preventing corona infection. In the last year, this drug has emerged as a possible option for the treatment of covid.

article thumbnail

Nine for 2022: International issues that are compelling, new or changed in 2022

Pharma Phorum

The next phase of the Covid-19 – from vaccines to treatments. New COVID-19 treatments will also be available in 2022, but they are not a panacea. Both companies have signed agreements to support access to these agents in low and middle-income countries.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

Pharma Phorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.